News
When sound drives wellness: Music’s expanding role in femtech

By Con Raso, Managing Director, Tuned Global
Music and technology leaders at Tuned Global, Endel and Bluesound Professional discuss intersection of art, tech, wellness and music.
The intersection of music and wellness is not new, but the shape of it is changing quickly.
Femtech innovation is evolving fast, and the decisions innovators make around content, technology, and licensing are creating a genuinely new kind of music business.
This space was explored during a panel at the 2025 Music Tectonics conference in Santa Monica, with other companies whose approaches to wellness music share very little in common beyond the category label.
The session, moderated by Andrew Stess, Head of Sales and Business Development for North America at music cloud platform Tuned Global, drew out a conversation between Graeme Harrison, Vice President & General Manager of Bluesound Professional, and Marina Guz, Chief Commercial Officer with Endel.
Stess opened with a deliberately broad question: what is wellness? The answers illustrated just how wide the category has become.
For context, Bluesound Professional makes networked audio hardware deployed across a range of environments, from gyms to hospitals to corporate offices.
The company works with services including Composure, which targets sleep improvement for people with dementia, and MoodSonic, which applies biophilic soundscaping to workplace environments.
“Wellness is different things to different services,” Bluesound Professional’s Harrison said.
“Fit Radio would look at wellness as being gyms and exercise and that sort of thing. Composure is about helping people with dementia, specifically sleep, go to sleep and stay asleep.
“With MoodSonic, wellness is all about the well workplace, getting well-certified and employee engagement, creating activity-based work where you can go to different areas of a workplace to achieve what you want; focus, relaxation, creativity, whatever.”
Endel’s Guz came at the question from a different angle.
The company generates AI-powered soundscapes for focus, relaxation, sleep and meditation, each personalised to the user’s biometric inputs.
“Can you sleep? Can you deal with stress? Are you grounded? What’s your general mindset towards things?” she said. “That’s what Endel is trying to really help you with.”
Art, Tech and Science

Marina Guz
For Endel, the music model is a little different from other music businesses.
Every soundscape is generated in real time, drawn from stems produced by Endel’s internal composers or in collaboration with external artists, and assembled dynamically based on user inputs including heart rate, time of day, weather, and movement.
“We always like to say we live at the intersection of tech, art, and science,” Guz said.
“The team has gone out and done a lot of research, we collaborate with a lot of scientists and researchers in the space to really understand what kind of sounds we need to play for you to fall asleep vs stay asleep vs when you wake up.”
The company’s founding team had musical backgrounds, including a neoclassical composer who has released on Decca, and a CEO whose deep interest in Brian Eno shaped the company’s foundational approach.
That grounding in composition distinguishes Endel’s output from what Guz sees as the broader wellness music category on streaming platforms.
The company’s first major artist collaboration was with Grimes. Since then it has worked with James Blake, Miguel, and others, building soundscapes that carry an artist’s sonic identity while adhering to scientific guidelines for the intended use case.
Endel was also, according to Guz, the first AI music company to sign deals with Universal Music Group and Warner Music Group.
The personalisation goes further than most listeners would expect.
Two people pressing play on the same Endel soundscape at the same time will hear different outputs, because the system continuously adapts to each user’s biometric state.
“If you and I, we’re in different locations, different age, different sex. Maybe you’re sitting down and walking around at different heart rates. Your soundscape will sound different than my soundscape because it will get personalised to the inputs that you give it,” Guz said.
“No track, no soundscape is ever the same in the app. It always gets generated on the fly for you in the moment based on the inputs.”
Hardware, Artists, and the AI Problem
Stess, whose work at Tuned Global is built around helping fitness, wellness and other companies navigate the complex music streaming and licensing space, steered the conversation toward implementation. The theory was covered.

Andrew Stess
What does the infrastructure look like in practice, and where do artists fit in it?
Harrison brought up the delivery layer, something the panel hadn’t dwelled on yet.
Bluesound Professional makes networked audio hardware that sits at the endpoint of everything the other two companies build, and there’s more going on there than the word “hardware” suggests.
Their devices are individually addressable network speakers, which means a service like MoodSonic can pull in real-time occupancy levels, temperature, and time of day to shift a workplace soundscape on the fly.
Their work with Composure goes further, using pillow sensors to measure sleep quality in dementia patients and adapting the audio output accordingly.
Harrison also raised something that landed quietly in the room: Model Context Protocol.
Developed initially by Anthropic and later adopted by OpenAI, Microsoft, and Google, it’s a standard that lets agentic AI communicate directly with connected devices.
When he asked who in the audience knew what it was, only a handful of hands went up.
“It completely subverts the controller interface,” he said.
“That means that we can control all of our devices via our AI agent of choice.”
On the question of where artists fit, Stess put it directly: how do you build something sustainable in wellness? Guz’s answer was blunt.
Much of the wellness streaming world runs on ghost producers and fake artist profiles built to generate playlist placements rather than careers.
“It’s all kind of ghost producers, fake artists that populate these playlists,” she said.
“On that side of the world, there can still be a lot done to promote more artists who want to actually move into the space.”
Endel is now launching Sources, a label dedicated to artist-centric wellness music, signing neoclassical and ambient artists who make the music but lack the platform.

Graeme Harrison
“We are signing just small artists, because there are a lot of amazing neoclassical artists who make music in the space, but they don’t really have a platform,” Guz said.
“We’re launching something that is really just humans making music for the space, no science, no tech, no anything, because that’s what’s really missing, at least on the streaming side of the business.”
Guz also flagged a complication specific to Endel.
The company has worked with AI since before it became a loaded term, and that history has become a liability.
The early collaborations with Grimes, James Blake, and Miguel drew real attention when generative soundscapes with named artists were still a novelty.
That novelty has since been swamped by a flood of low-effort AI-generated content filling wellness playlists across every major platform.
“AI is associated, especially in the wellness space, with slop,” she said.
“So much content, cover artwork, is being generated, and everything looks terrible and a lot of it sounds terrible, and so we are being grouped into that same thing, even though we’re really not [that] at all”
The questions the panel kept returning to, around licensing, metadata, artist engagement, and the AI content quality problem, are the sort Tuned Global works through with clients building music into health and wellness products.
The wellness music space is growing, the licensing challenges are real, and the opportunity for artists willing to engage seriously with it is there.
The infrastructure, whether hardware, soundscape technology, or a fitness platform’s back end, is further along than most of the music industry has noticed.
About Con Raso, Managing Director of Tuned Global
Con Raso is an entrepreneur passionate about innovation, new technologies, and start-ups.
Over the last few decades he has focused on creating innovative mobile and online distribution models within the B2C entertainment market, enabling brands to utilise music as a marketing tool, via unique customer engagement strategies.
Being inherently well-versed in both technology and music, Con ensures our solutions are aesthetically pleasing, engaging and disruptive.
About Tuned Global
Tuned Global is the data-driven music cloud platform that empowers businesses to integrate commercial music into their apps and launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, rights management systems, Ai-enabled music discovery, and customisable white-label streaming apps.
Our turnkey solutions for music, audio, and video — coupled with advanced AI capabilities and a broad ecosystem of third-party music tech integrations — make us the most comprehensive platform for powering any digital music project.
We streamline complexities in licensing, rights management, and content delivery, enabling rapid innovation and bringing new ideas to life. Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, gaming, fitness, health, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.
Learn more at tunedglobal.com
Mental health
Yoga and omega-3 as effective as therapy for depression in pregnancy, research finds

Yoga and omega-3 supplements may be as effective as talking therapies for pregnancy depression, a major review suggests.
Globally, nearly one in three pregnant women experience depression, but most receive no treatment.
When support is available, women are often directed towards talking therapies such as cognitive behavioural therapy, or CBT, and mindfulness.
CBT is a structured talking therapy that helps people identify and change patterns of thought and behaviour affecting their mental health.
The review examined 115 clinical trials involving more than 12,000 participants across 30 countries.
It found that yoga, massage, omega-3 supplements and bright light therapy were broadly as effective as talking therapies at reducing depression symptoms during pregnancy.
Bright light therapy involves controlled exposure to bright light and is sometimes used to treat mood conditions.
The findings point to the importance of social support and increased connection, as all these approaches offer some element of contact or guided support.
Led by King’s College London, the research brought together trial evidence across every type and format of treatment for antenatal depression under a common framework.
Antenatal depression is depression that occurs during pregnancy.
The study was conducted as part of HappyMums, a European consortium led by the University of Milan that aims to improve mental health support during pregnancy and after birth.
Carmine Pariante, professor of biological psychiatry, said: “This is the most comprehensive analysis of treatments for depression in pregnancy ever conducted, and the findings should prompt a rethink of how we support women during this critical period.
“The evidence is clear that there is no single best approach. What matters is that women have access to a range of options, and that clinicians feel equipped to offer them.”
The researchers said yoga and omega-3 supplements could be legitimate treatment options, rather than stopgaps, for women on waiting lists or those who struggle to access mental health support.
However, the studies differed considerably in design, sample size and how results were measured, so the findings should be interpreted with care.
The team said non-psychological approaches could help women cope with long waits for care without ruling out other treatments alongside them.
Digital and online interventions, including apps and telephone-based support, were also found to be as effective as face-to-face treatment.
Researchers said this could affect how antenatal depression is managed, particularly for women who cannot travel or face long waits for in-person care.
The team found no randomised controlled trials of pharmaceutical treatments for antenatal depression, despite antidepressants being widely prescribed for depression outside pregnancy.
A randomised controlled trial is a study in which participants are randomly assigned to different treatment groups, allowing researchers to compare outcomes more fairly.
Evidence for drug treatment during pregnancy therefore relies on indirect research rather than trials carried out during pregnancy, reflecting long-standing caution around testing medicines in pregnant populations.
NICE guidelines recommend antidepressants for moderate to severe depression in pregnancy, while evidence from outside formal pregnancy trials suggests they can be safe and effective.
However, the researchers said trials are still needed, particularly for women who cannot access or engage with other forms of support.
Riddhi Laijawala, trial manager and PhD student, said: “Depression in pregnancy is common, but it is not inevitable, and it is treatable. What this review shows is that the options available to women are broader than many people realise.
“A yoga class, music therapy, or an online programme may not sound like clinical treatment, but the evidence suggests they can make a real difference, and for many women they may be easier (and quicker) to access than a course of therapy.”
Depression during pregnancy affects an estimated 28.5 per cent of pregnant people worldwide, but only around one in five receives appropriate and timely treatment.
The team said closing this treatment gap should be a priority for health systems because the condition can affect both parent and child.
The HappyMums project is supported by the European Union’s Horizon Europe research and innovation programme.
Hormonal health
Type 2 diabetes rising among young women, experts warn

Type 2 diabetes is rising among women in their 20s in England, with experts warning of a worrying increase since the Covid pandemic.
The rise has largely occurred since the pandemic and is closely linked to increasing obesity levels, according to an analysis of NHS data from 2011 to 2024.
The condition is serious and can lead to severe complications, including heart attacks and strokes.
Diabetes UK said it tends to be more aggressive when it develops at a younger age, raising the risk of serious complications and shorter lives.
The charity said early diagnosis is vital for people at risk to help prevent long-term organ damage.
The condition can sometimes be put into remission through healthy eating and maintaining a healthy weight, without relying on glucose-lowering medicines.
Researchers said newer obesity treatments, including GLP-1 injections and pills, may also help alongside healthy eating advice.
About 90 per cent of the six million people living with diabetes in the UK have type 2 rather than type 1, or insulin-dependent, diabetes.
The risk increases with age, and older adults still account for the largest proportion of new diagnoses.
However, NHS England estimates suggest that 12,000 people under 30 are now living with the condition, with women making up more of the younger cases.
Common symptoms include feeling very tired, urinating more often than usual and feeling thirsty all the time.
Researchers at Imperial College London analysed NHS data from the English National Diabetes Audit to examine trends over time.
The figures showed that cases are falling slightly among older adults, who still account for the largest share of new diagnoses.
However, diagnoses are increasing rapidly among people under 40, with some of the sharpest rises among women aged 20 to 29.
Body mass index at diagnosis has also been rising more quickly among younger adults than in older age groups, pointing to obesity as a likely factor.
Body mass index, or BMI, is a measure of obesity based on a person’s height and weight.
Separate NHS data for England shows obesity rates have worsened since the pandemic, with nearly one in three people now affected.
The largest increases over time have been among younger adults.
Between 2019 and 2025, new obesity cases rose by 16 per cent among people aged 20 to 29 and by almost 20 per cent among those aged 30 to 39.
Rates fell among adults aged 60 to 79 over the same period.
Lead researcher Dr Shivani Misra said: “We think that the earlier onset of severe obesity in young people is increasing their type 2 diabetes risk in early life and pulling down their age at diagnosis.
“This is really worrying given the poor health outcomes from early-onset type 2 diabetes.”
Misra said much of the discussion about rising rates among younger people had focused on ethnic minority groups, which have traditionally been considered at higher risk.
However, the new data suggests the trend extends well beyond those communities.
She added: “We now see that incidence is also increasing in white populations too, showing that this public health challenge is broadening across the generations.”
Diabetes UK said better follow-up care is also needed for mums-to-be diagnosed with gestational diabetes during pregnancy because it raises the risk of developing type 2 diabetes after childbirth.
Some studies have suggested that the risk of developing the condition may also increase after being ill with Covid, although the evidence remains inconclusive.
Wellness
AstraZeneca drug approved for breast cancer in EU

AstraZeneca’s breast cancer drug Etcamah has been approved in the EU as part of a combination treatment for advanced disease.
The European Commission acted on a positive opinion from the Committee for Medicinal Products for Human Use, the Cambridge, England-based drug maker said.
The decision followed positive results from the Serena-6 phase III trial, which showed a 56 per cent reduction in the risk of disease progression in advanced oestrogen receptor-positive breast cancer.
A phase III trial is a large, late-stage study used to assess a treatment’s safety and effectiveness before wider regulatory approval.
Oestrogen receptor-positive breast cancer is a form of the disease that can grow in response to the hormone oestrogen.
Etcamah, whose generic name is camizestrant, was tested in combination with a cyclin-dependent kinase 4/6 inhibitor.
Known as CDK4/6 inhibitors, these medicines block proteins that help cancer cells grow and divide.
AstraZeneca said the Etcamah combination has also been approved in Japan, the UAE and Saudi Arabia based on the Serena-6 trial results.
The company said breast cancer remains the leading cause of cancer death among women in Europe, with more than 140,000 deaths and more than 540,000 patients diagnosed in 2024.
AstraZeneca shares were down 0.6 per cent at 12,628 pence in London on Thursday.
News2 weeks agoNew menopause drug approved for use by NHS in Scotland
Hormonal health1 week agoStardust period tracker shares health data, study reveals
Entrepreneur6 days agoZero Candida market set to reach over US$2 billion by 2030 – report
News2 weeks agoWomen’s health draws record $1.55bn in equity as capital spreads beyond the mega-rounds
Insight2 weeks agoSoftening ovaries could extend fertility as women age, study suggests
Entrepreneur2 weeks agoOnto Health acquires diagnostics software company Levy Health
Wellness1 week agoCongress urged to invest over $20bn to close women’s health gap
Mental health7 days agoNearly 60% of young women get health advice from influencers, research finds












